CNS Pharmaceuticals' Berubicin trial for recurrent GBM did not show a significant survival benefit over Lomustine. The study reported no cardiotoxicity with Berubicin, unlike other anthracyclines ...

Berubicin showed clinically relevant outcomes comparable to Lomustine across multiple endpoints, but not a statistically significant difference in overall survival, the primary endpoint.